Rua Bioscience's FY26 results highlight a 71% surge in customer revenue driven by international expansion, yet the company continues to face significant losses and going concern risks.
- 71% increase in customer revenue to NZ$2.58 million
- Secured NZ$10 million UK export deal over two years
- Loss before tax reduced slightly to NZ$3.36 million
- Raised NZ$2.3 million in new capital during FY26
- Going concern risks persist despite funding and operational progress
Revenue Growth Fueled by International Expansion
Rua Bioscience (NZX:RUA) reported a substantial 71% increase in customer revenue for FY26, reaching NZ$2.58 million, as its export-led strategy gained traction across multiple international markets. The company strengthened its foothold in Australia and Germany, entered new territories including the United Kingdom, Czechia, and Canada, and continued to grow its home base in Aotearoa New Zealand. This growth was underpinned by a landmark UK sales and distribution agreement expected to generate more than NZ$10 million over two years, marking Rua’s largest export contract to date.
Operational Advances and Product Expansion
FY26 saw Rua broaden its product portfolio domestically with the introduction of a medical vaporising device and regulatory approval for five additional products, positioning the company for further growth in New Zealand’s estimated NZ$60 million medicinal cannabis market. In Australia, the world’s second-largest medicinal cannabis market, Rua nearly doubled sales revenue and margin through strengthened clinic partnerships despite ongoing regulatory reviews and competitive pressures.
Internationally, Rua made strategic inroads by exporting live cannabis clones to Canada, establishing a genetic base in one of the largest global cannabis markets. It also achieved initial sales in Czechia following regulatory changes that opened new prescribing opportunities. In Germany, despite a challenging market environment marked by regulatory reviews and oversupply, Rua expanded its product range and negotiated supplier cost reductions expected to improve margins.
Financial Performance and Capital Raising
While revenue growth was robust, Rua’s FY26 loss before tax remained substantial at NZ$3.36 million, a modest 3% reduction from the previous year. The operating loss before financing costs narrowed by 8% to NZ$3.05 million. The company’s cash position improved with cash and equivalents rising to NZ$533,698 from NZ$241,421, supported by NZ$2.3 million in new shareholder capital raised through private placements and a rights offer during the year.
Post year-end, Rua secured a convertible note facility capped at NZ$600,000 to accelerate inventory purchases for its UK expansion, with NZ$150,000 drawn to date. The company also rolled over $592,000 of existing debt facilities while repaying $48,000 upon maturity, reflecting ongoing efforts to manage liquidity amid continued cash outflows.
Going Concern Risks Temper Outlook
Despite operational progress and funding initiatives, Rua faces material uncertainties regarding its ability to continue as a going concern. The Board’s cash flow forecasts indicate insufficient liquidity to meet minimum expenditure commitments over the next 12 months without further capital raising or asset sales. The company is actively pursuing the sale of its Gisborne facility, with proceeds expected to reduce debt and provide additional working capital.
The Directors remain cautiously optimistic that sales growth across established and emerging markets, combined with new product launches and strategic partnerships, will drive the company towards profitability and sustainable cash flow. However, they acknowledge that failure to meet revenue targets or delays in funding could jeopardise ongoing operations.
Social Impact and Community Commitment
Rua continues to invest in social and economic initiatives in its home region of Tairāwhiti, including pioneering cultivation of psilocybin mushrooms for clinical trials, maintaining a Compassionate Access Programme supporting up to 52 patients monthly, and awarding scholarships to local students. These efforts underscore Rua’s dual focus on commercial growth and community wellbeing.
Bottom Line?
Rua’s impressive revenue gains underscore market potential, but sustained losses and cash constraints highlight the urgency of securing further funding and executing growth plans.
Questions in the middle?
- Will Rua successfully convert its UK sales agreement into sustained revenue growth?
- How quickly can the company finalise the Gisborne facility sale to bolster liquidity?
- Can Rua achieve profitability amid regulatory uncertainties and competitive pressures?